Want to see MEDS full AI Analyst Report?
Top Page
DataMeds AI
(NASDAQ:MEDS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▲(108.33% Upside)
Action:Reiterated
Date:10/26/26
The score is held down primarily by very weak financial performance (sharp revenue contraction, extreme losses, and significant ongoing cash burn) and a strained capital position. Technicals also reflect a weak trend with negative momentum. Offsetting factors include constructive corporate developments (compliance regained and balance-sheet/legal clean-up), but dilution risk and lack of profitable operations keep the overall profile high risk.
Positive Factors
Liability Reduction
Eliminating approximately $19 million of liabilities materially reduces legal and balance-sheet overhang. The settlement can improve capitalization, simplify future reporting, and preserve management attention for operations, although it does not by itself resolve the company’s operating losses or cash needs.
Negative Factors
Severe Revenue and Margin Deterioration
Sharp revenue contraction alongside materially negative gross profit and a roughly -546% net margin indicates that the current cost structure is not aligned with business scale. Unless operations improve substantially, weak profitability can continue consuming capital and limit sustainable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Liability Reduction
Eliminating approximately $19 million of liabilities materially reduces legal and balance-sheet overhang. The settlement can improve capitalization, simplify future reporting, and preserve management attention for operations, although it does not by itself resolve the company’s operating losses or cash needs.
Read all positive factors
DataMeds AI (MEDS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.88M
Dividend YieldN/A
Average Volume (3M)13.33M
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue Growth-78.16%
EPS Growth-15.07%
CountryUS
Employees31
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,515,862
10 Day Avg. Volume869,255
30 Day Avg. Volume13,329,233
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap3.88
Enterprise Value/Revenue4.78
Enterprise Value/Gross Profit-3.82
Enterprise Value/Ebitda-0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DataMeds AI Business Overview & Revenue Model
Company Description
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enab...
DataMeds AI Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.02M | 23.34M | 18.13M | 0.00 | 32.78M |
| Gross Profit | -10.04M | -9.64M | 1.77M | 0.00 | 5.75M |
| EBITDA | -56.41M | -93.48M | -4.91M | -2.88M | -369.03K |
| Net Income | -88.28M | -101.27M | -6.86M | -2.90M | -2.74M |
Balance Sheet | |||||
| Total Assets | 32.76M | 30.46M | 57.33M | 338.36K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 2.46M | 42.57K | 1.03M | 1.36K | 0.00 |
| Total Debt | 32.62M | 24.77M | 25.11M | 700.00K | 0.00 |
| Total Liabilities | 52.26M | 42.91M | 50.60M | 3.24M | 5.25K |
| Stockholders Equity | -19.50M | -12.45M | 6.73M | -2.90M | -5.25K |
Cash Flow | |||||
| Free Cash Flow | -13.59M | -10.86M | -1.60M | -349.14K | 0.00 |
| Operating Cash Flow | -13.74M | -10.86M | -1.22M | -349.14K | 0.00 |
| Investing Cash Flow | -923.70K | -881.53K | 469.07K | 0.00 | 0.00 |
| Financing Cash Flow | 16.70M | 10.75M | 1.78M | 350.50K | 0.00 |
DataMeds AI Technical Analysis
Negative
0.96
Price Trends
2.44
Negative
2.67
Negative
6.05
Negative
Market Momentum
-0.18
Positive
42.44
Neutral
11.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MEDS, the sentiment is Negative. The current price of 0.96 is below the 20-day moving average (MA) of 2.85, below the 50-day MA of 2.44, and below the 200-day MA of 6.05, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 42.44 is Neutral, neither overbought nor oversold. The STOCH value of 11.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDS.
DataMeds AI Risk Analysis
DataMeds AI disclosed 64 risk factors in its most recent earnings report. DataMeds AI reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DataMeds AI Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $61.89B | 23.99 | 106.43% | 0.74% | 5.09% | 38.10% | |
71 Outperform | $111.99B | 25.59 | -194.39% | 0.36% | 8.84% | 48.98% | |
61 Neutral | $9.47B | 24.55 | 12.37% | ― | 6.49% | 10.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | $9.88M | -0.05 | 877.58% | ― | -78.16% | -15.07% | |
43 Neutral | $17.92M | -0.06 | 63.40% | 0.02% | -69.68% | 74.88% |
* General Sector Average
MEDS
DataMeds AI
2.20
-37.12
-94.40%
COR
Cencora
324.35
-14.28
-4.22%
HSIC
Henry Schein
84.96
22.06
35.07%
MCK
McKesson
960.56
138.27
16.81%
ACH
Accendra Health
0.23
-4.73
-95.30%
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
2.18
-23.02
-91.35%
DataMeds AI Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
DataMeds AI Pursues Transformative Telehealth IP Acquisition
Positive
Oct 26, 2026
On October 21–22, 2026, DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent with Datavault AI, EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors, Tollo Health and REBOOT Health AI to licen...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
DataMeds AI Regains Nasdaq Equity Compliance Status
Positive
Oct 20, 2026
On October 20, 2026, DataMeds AI, Inc., a Tampa-based health technology and pharmacy services company trading on Nasdaq under MEDS, reported that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) governing minimum stockholders’ ...
Business Operations and StrategyPrivate Placements and Financing
DataMeds AI Licenses REBOOT Platform, Issues Equity
Positive
Oct 16, 2026
On October 13, 2026, DataMeds AI, Inc. entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc., securing an exclusive U.S. license, within a defined field of use, to REBOOT’s patents and A...
Business Operations and StrategyStock BuybackFinancial DisclosuresLegal Proceedings
DataMeds AI Restructures Equity and Forms Licensing Partnership
Positive
Oct 13, 2026
As of October 13, 2026, DataMEDS AI reported stockholders’ equity above $2.5 million following a series of legal and strategic transactions. The company settled long-running disputes tied to a 2023 Membership Interest Purchase Agreement by p...
Business Operations and StrategyStock BuybackFinancial DisclosuresLegal Proceedings
DataMeds AI Settles Litigation, Strengthens Balance Sheet
Positive
Sep 17, 2026
On September 11, 2026, DataMEDS AI, Inc. entered into a settlement agreement with several parties, including former counterparties to a Membership Interest Purchase Agreement dated May 11, 2023. The agreement follows reciprocal lawsuits in Florida...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
DataMeds AI Acquires Helomics to Expand Cancer Platform
Positive
Sep 16, 2026
On September 11, 2026, DataMEDS AI entered a stock purchase agreement to acquire all outstanding shares of Helomics Corporation from Axe Compute Inc., paying with 636,328 DataMEDS common shares and a $1,363,672 convertible promissory note that mat...
Business Operations and StrategyDividends
DataMeds AI Announces Token-Based Shareholder Distribution Plan
Neutral
Aug 14, 2026
Datavault AI Inc. plans a voluntary one-time distribution of Dream Bowl 2026 Meme Coin tokens to record holders of DataMEDS AI common stock as of August 7, 2026, with fifty tokens allocated per share. The payment is scheduled to begin on September...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.